Startseite The crystal structure of 3-bromo-6-methoxy-2-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine, C13H19BBrNO3
Artikel Open Access

The crystal structure of 3-bromo-6-methoxy-2-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine, C13H19BBrNO3

  • Ji-Run Zhang , Hao Deng und Tong Liu ORCID logo EMAIL logo
Veröffentlicht/Copyright: 13. Dezember 2019

Abstract

C13H19BBrNO3, triclinic, P1̄ (no. 2), a = 6.5459(3) Å, b = 11.2565(5) Å, c = 11.8529(5) Å, α = 106.938(2)°, β = 105.657(2)°, γ = 106.628(2)°, V = 738.71(6) Å3, Z = 2, Rgt(F) = 0.0286, wRref(F2) = 0.0641, T = 173 K.

CCDC no.: 1958725

The molecular structure is shown in the figure. Table 1 contains crystallographic data and Table 2 contains the list of the atoms including atomic coordinates and displacement parameters.

Table 1:

Data collection and handling.

Crystal:Colourless block
Size:0.16 × 0.11 × 0.08 mm
Wavelength:Mo Kα radiation (0.71073 Å)
μ:2.79 mm−1
Diffractometer, scan mode:Bruker APEX-II, φ and ω
θmax, completeness:27.5°, 99%
N(hkl)measured, N(hkl)unique, Rint:9092, 3356, 0.031
Criterion for Iobs, N(hkl)gt:Iobs > 2 σ(Iobs), 2931
N(param)refined:178
Programs:Bruker [1], SHELX [2], [3], Olex2 [4]
Table 2:

Fractional atomic coordinates and isotropic or equivalent isotropic displacement parameters (Å2).

AtomxyzUiso*/Ueq
B10.6832(4)0.2552(2)0.46623(19)0.0235(4)
Br10.48104(4)0.29330(2)0.01250(2)0.03610(8)
C10.7962(4)0.1217(2)−0.02188(18)0.0359(5)
H1A0.8880800.206264−0.0237540.054*
H1B0.6487630.076348−0.0957810.054*
H1C0.8809970.062582−0.0249930.054*
C20.7514(3)0.15211(19)0.09884(17)0.0259(4)
C30.6202(3)0.22479(19)0.12749(17)0.0261(4)
C40.5935(3)0.25312(19)0.24355(17)0.0262(4)
H40.5030530.3028690.2623920.031*
C50.6984(3)0.20908(18)0.33224(16)0.0237(4)
C60.8221(3)0.13227(18)0.29263(16)0.0236(4)
C71.0333(4)−0.0014(2)0.33081(19)0.0318(4)
H7A0.929361−0.0742350.2471960.048*
H7B1.078136−0.0405330.3924990.048*
H7C1.1715920.0533720.3236000.048*
C90.7191(3)0.28905(19)0.67033(16)0.0245(4)
C100.6096(3)0.38222(19)0.62608(16)0.0253(4)
C110.7802(4)0.5269(2)0.6734(2)0.0354(5)
H11A0.9185400.5269280.6562760.053*
H11B0.8233450.5726550.7655340.053*
H11C0.7088440.5746430.6288860.053*
C120.3928(4)0.3792(2)0.65081(19)0.0345(5)
H12A0.3354800.4394670.6191510.052*
H12B0.4287600.4093830.7428320.052*
H12C0.2742900.2867300.6064050.052*
C130.9224(4)0.3610(2)0.79788(18)0.0348(5)
H13A0.9850130.2964130.8165620.052*
H13B0.8711520.3991210.8651870.052*
H13C1.0423450.4338400.7943770.052*
C140.5439(4)0.1645(2)0.66675(18)0.0321(4)
H14A0.4141040.1194980.5835980.048*
H14B0.4871820.1913290.7346520.048*
H14C0.6171130.1022040.6796750.048*
N10.8487(3)0.10511(16)0.18210(14)0.0262(3)
O10.8042(2)0.24100(13)0.57073(11)0.0259(3)
O20.5450(2)0.32268(13)0.48730(11)0.0271(3)
O30.9169(2)0.08245(13)0.37358(12)0.0276(3)

Source of material

All chemicals, reagents and solvents are of analytical grade and commercially available. To a 3 mouth flask, bis(pinacolato)diboron (6.91 g, 27.21 mmol), bipyridine (0.19 g, 1.21 mmol) and bis[(1,5-cyclooctadiene)(methanolato)iridium] (0.041 g, 0.062 mmol) were added and n-hexane (100 mL) was injected into the 3 mouth flask at 25 °C then the reaction mixture was stirred under a nitrogen atmosphere. After stirring for an hour, 3-bromo-6-methoxy-2-methylpyridine (5.0 g, 24.74 mmol) was added under a nitrogen atmosphere. The reaction mixture was stirred at 60 °C for 1 hour under nitrogen. The progress of the reaction was monitored by TLC. On completion, the reaction mixture was poured into water and filtered, then the filtrate was extracted with ethyl acetate. The organic phase was evaporated with vacuum distillation to afford the crude product (8.01 g). The crude product was recrystallized from n-hexane (100 mL) twice to afford a crystalline solid (7.23 g, 89.03%). 1H NMR (400 MHz, CDCl3) δ [ppm] 8.12 (s, 1H), 4.02 (s, 3H), 2.47 (s, 3H), 1.39 (s, 12H).

Experimental details

All hydrogen atoms were placed in geometrically calculated positions. The Uiso values of the hydrogen atoms of methyl groups were set to 1.5 Ueq(Cmethyl) and the Uiso values of all other hydrogen atoms were set to 1.2 Ueq.

Comment

The compound 3-bromo-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine, which shows some similarities with the title compound has applications in the field of medicine, organic synthesis and fine chemicals. It is an important intermediate for the synthesis of cholinergic drugs which can treat gastrointestinal diseases [5]. Similar compounds participate in the synthesis of oxazolidinone derivatives for modulators of mGluR5 [6]. In the synthesis of organic electroluminescent devices [7].

The structure of the title compound was clarified by spectroscopy and X-ray diffraction. The crystal structure shows that there is one molecule in the asymmetric unit. The crystal structure shows that the molecules are stabilized by intermolecular hydrogen bonds which are C14—H14C⋯C7 (distance = 2.846 Å), C7—H7B⋯O1 (distance = 2.695 Å), C11—H11C⋯O2 (distance = 2.605 Å) and the intermolecular packing is stabilized by the van der Waals forces. All bond lengths and angles are comparable to those in the literature [8], [9].

Acknowledgements

This work was supported by the Science and Technology Cooperation Project in Guizhou Province (LH20177252), the Science and Technology Development Project of Guizhou Technology Program (SY20133092, SY20143052) and the Guizhou University’s Academic New Seedling Cultivation and Innovation Exploration Project in 2017 (20175788).

References

1. Bruker. SMART APEX software (5.624) for SMART APEX detector. Bruker Axs Inc., Madison, WI, USA (2001).Suche in Google Scholar

2. Sheldrick, G. M.: SHELXTL, Version 6.10. Bruker AXS Inc., Madison, WI, USA (2000).Suche in Google Scholar

3. Sheldrick, G. M.: A short history of SHELX. Acta Crystallogr. A64 (2008) 112–122.10.1107/S0108767307043930Suche in Google Scholar PubMed

4. Dolomanov, O. V.; Bourhis, L. J.; Gildea, R. J.; Howard, J. A. K.; Puschmann, H.: OLEX2: a complete structure solution, refinement and analysis program. J. Appl. Crystallogr. 42 (2009) 339–341.10.1107/S0021889808042726Suche in Google Scholar

5. Voisin, A. S.; Bouillon, A.; Lancelot, J. C.; Aurelien, L.; Rault, S.: Synthesis of novel halo-oxybispyridines, new building blocks in cholinergic medicinal chemistry. Tetrahedron 62 (2006) 6000–6005.10.1016/j.tet.2006.04.002Suche in Google Scholar

6. Degnan, A. P.; Hong, H.; Snyder, L. B.; Fukang, Y.; Gillman, K. W.; Parker, M. F.: Oxazolidinones as modulators of mGluR5: Patent: WO2012064603, (2012).Suche in Google Scholar

7. Young-Mook, L.; Su-Hyun, L.; Hyun-Ju, K.; Chi-Sik, K.: Phosphorous host material and organic electroluminescent device comprising the same: Patent: WO2016186321, (2016).Suche in Google Scholar

8. Sopková-de Oliveira Santos, J.; Lancelot, J.-C.; Bouillon, A.; Rault, S.: 2-(6-Bromopyridin-3-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane and (6-bromopyridin-3-yl)boronic acid, new bifunctional building blocks for combinatorial chemistry. Acta Crystallogr. C59 (2003) o111–o113.10.1107/S0108270103000908Suche in Google Scholar PubMed

9. Miller, S. L.; Chotana, G. A.; Fritz, J. A.; Chattopadhyay, B.; Maleczka, R. E.; Smith, M. R.: C—H Borylation catalysts that distinguish between similarly sized substituents like fluorine and hydrogen. Org. Lett. 21 (2019) 6388–6392.10.1021/acs.orglett.9b02299Suche in Google Scholar PubMed

Received: 2019-10-11
Accepted: 2019-11-12
Published Online: 2019-12-13
Published in Print: 2020-02-25

©2019 Ji-Run Zhang et al., published by De Gruyter, Berlin/Boston

This work is licensed under the Creative Commons Attribution 4.0 Public License.

Artikel in diesem Heft

  1. Frontmatter
  2. Synthesis and crystal structure of bis{5-fluorine-2-(((4-(1-(methoxy-imino)ethyl)phenyl) imino)methyl)phenolato-κ2N,O}copper(II), C32H28CuF2N4O4
  3. Redetermination of the crystal structure of N′-(3-ethoxy-2-hydroxybenzylidene)-4-fluorobenzohydrazide monohydrate, C16H17FN2O4
  4. The crystal structure of (E)-N′-(1-(3-chloro-4-fluorophenyl) ethylidene)-2-hydroxybenzohydrazide, C15H12ClFN2O2
  5. Crystal structure of (E)-N-[4-(1H)-imidazolyl phenyl]-(2-methylphenyl)methanimine, C17H15N3
  6. The crystal structure of 1-benzyl-4-(2-(phenylethynyl)phenyl)-1H-1,2,3-triazole, C23H17N3
  7. Crystal structure of catena-poly[{μ2-1,5-bis(diphenylphosphanyl)pentane-κ2P:P′}dichloridocadmium(II)], C29H30CdCl2P2
  8. Crystal structure of methyl (E)-N2-((3-methylquinolin-8-yl)sulfonyl)-Nω-nitro-L-argininate - ethanol (1/1), C19H28N6O7S
  9. The crystal structure of trans-carbonyl-(diphenylcyclohexyl-phosphine-κP)iodidomethyl-(2-oxopyridin-1(2H)-olato-κ2O,O′)rhodium(III), C25H28INO3PRh
  10. Crystal structure of N-(amino(pyrazin-2-yl)methylene)-6-methylpyridin-1-ium-3-carbohydrazonate-κ3O,N,N′)-(dinitrato-κ1O)zinc(II), C12H12N8O7Zn
  11. The crystal structure of dichlorido-(tris(2-benzimidazolylmethyl)amine-κ4N,N′,N′′,N′′′)chromium(III) chloride — methanol (1/3), CrC27H33Cl3N7O3
  12. Crystal structure of catena-poly[aqua(μ4-piperazine-1,4-bis(2-hydroxypropanesulfonato-κ8O,O′:O′,N:N′,O′′:O′′,O′′′))silver(I)], C10H24Ag2N2O10S2
  13. Crystal structure of bis(μ3-oxido)-bis(μ2–2,3,4,5-tetrafluorobenzoato-κ2O:O′)-bis(2,3,4,5-tetrafluorobenzoato-κO)-oktakis(3-chlorobenzyl-κC)tetratin(IV), C84H52Cl8F16O10Sn4
  14. Crystal structure of (E)-1-{4-[(4-fluoro-2-hydroxybenzylidene)amino]phenyl}ethanone O-methyl oxime, C16H15FN2O2
  15. Crystal structure of catena-[(bis(O,O′-diethyl dithiophosphato-S,S′)-μ2-1,2-bis(3-pyridylmethylene)hydrazine-N,N′)zinc(II)], {C20H30N4O4P2S4Zn}n
  16. Crystal structure of methyl 2-(4-(3-iodopyrazolo[1,5-a]pyrimidin-6-yl)phenyl)acetate, C15H12IN3O2
  17. Crystal structure of hexacarbonyl-(μ2-methanoato-k2O:O′)-(μ2–bis(di-p-tolylphosphino)cyclohexylamine-κ2P:P′)dirhenium(I), C42H45NO8P2Re2
  18. The cocrystal structure of 1′-hydroxy-1H,1′H-[5,5′-bitetrazol]-1-olate and 1,10-phenanthrolin-1-ium, C14H10N10O2
  19. The crystal structure of 1-benzyl-2-((4-(tert-butyl)phenyl)ethynyl)pyridin-1-ium bromide,C24H24BrN
  20. Crystal structure of (5,5′-bitetrazole-1,1′-diolate)-bis(1,10-phenanthroline)-copper(II), C26H16CuN12O2
  21. Crystal structure of bis(ammonium) diaqua-tetrakis(4-hydroxybenzoato)-manganese(II) tetrahydrate, [NH4]2[C28H24MnO14] ⋅ 4(H2O)
  22. The crystal structure of 3-chloro-1-hydrazino-2,4,6-trinitrobenzene, C6H4ClN5O6
  23. Crystal structure of catena-[(μ2-pyrazine-κ2N:N′)-bis(O,O′-di-ethyldithiophosphato-κ2S,S′)cadmium(II)], {C12H24CdN2O4P2S4}n
  24. Crystal structure of catena-poly[(μ2-pyrazine-N,N′)-bis(O,O′-di-isopropyldithiophosphato-S,S′)cadmium(II) acetonitrile di-solvate], [C16H32CdN2O4P2S4⋅2(C2H3N)]n
  25. Crystal structure of catena-poly{(μ2-N1,N2-bis[(pyridin-4-yl)methyl]ethanediamide-κ2N:N′)-bis(O,O′-di-isopropyldithiophosphato-κ1S)zinc(II)} — acetonitrile (1/1), C26H42N4O6P2S4Zn⋅C2H3N
  26. Crystal structure of tetraqua-bis(4-(hydroxymethyl)benzoato-κO)cobalt(II), C16H22O10Co
  27. Crystal structure of catena-[(bis(O,O′-diethyl dithiophosphato-S,S′)-μ2-1,2-bis(4-pyridylmethylene)hydrazine-N,N′)cadmium(II)], {C20H30CdN4O4P2S4}n
  28. Crystal structure of catena-poly[(μ2-1,2-bis(3-pyridylmethylene)hydrazine-κ2N:N′)-bis(O,O′-dimethyl dithiophosphato-κ2-S,S′)cadmium(II)], {C16H22CdN4O4P2S4}n
  29. Crystal structure of catena-poly[(bis(O,O′-diethyl dithiophosphato-κ2S,S′)-μ2-1,2-bis(3-pyridylmethylene)hydrazine-κ2N:N′)cadmium(II)], {C20H30CdN4O4P2S4}n
  30. The crystal structure of catena-poly[(E)-2-(((5-((trimethylstannyl)thio)-1,3,4-thiadiazol-2-yl)imino)methyl)phenol], C12H15N3OS2Sn
  31. Crystal structure of dichlorido(N-o-tolyl-1,1-di-p-tolylphosphanamine–κ1P)-(methoxydi-p-tolylphosphane-κ1P)palladium(II), C36H39Cl2NOP2Pd
  32. The crystal structure of the triclinic polymorph of hexameric (trimethylsilyl)methyllithium, C24H66Li6Si6
  33. Crystal structure of bis(hydroxydi(pyridin-2-yl)methanolato-κ3N,N′O)cobalt(III) 7,7,8,8-tetracyanoquinodimethane, C34H22CoN8O4
  34. Synthesis and crystal structure of benzyl 5-oxo-5-phenyl-2-(quinolin-2-yl)pentanoate, C27H23NO3
  35. Crystal structure of 5,5-dimethyl-3-oxocyclohex-1-en-1-yl 4-(2,2-dichloroacetyl)-3,4-dihydro-2 H-benzo[b][1,4]oxazine-7-carboxylate, C19H19Cl2NO5
  36. Crystal structure of dipentyl 2,5-dihydroxycyclohexa-1,4-diene-1,4-dicarboxylate, C18H28O6
  37. The crystal structure of catena-poly[diaqua-(μ4-5-(benzo[d]thiazol-2-yl)benzene-1,3-dicarboxylate-κ4O,O′:O′′,O′′′)-(μ4-5-(benzo[d]thiazol-2-yl)benzene-1,3-dicarboxylate-κ4O,O′:O′′,O′′′)dicadmium(II)], C30H18Cd2N2O10S2
  38. Crystal structure of 2,7-diiodo-1,3,6,8-tetramethyl-bis(difluoroboron)-1,2-bis((1H-pyrrol-2-yl)methylene)hydrazine, C14H14B2F4I2N4
  39. A dinuclear Eu(III) complex in the crystal structure of dodecaaqua-bis(μ2-4-(1H-tetrazol-5-yl)benzoato-κ2O:O′) bis(5-(4-carboxylatophenyl)tetrazol-1-ide) tetrahydrate, C32H50Eu2N16O24
  40. Crystal structure and anti-inflammatory activity of (3E,5E)-3-(2-fluorobenzylidene)-1-((4-fluorophenyl)sulfonyl)-5-(pyridin-3-ylmethylene)piperidin-4-one, C24H18F2N2O3S
  41. Crystal structure and anti-inflammatory activity of (3E,5E)-3-(2-fluorobenzylidene)-1-((4-acetamidophenyl)sulfonyl)-5-(pyridin-3-ylmethylene)piperidin-4-one-methanol-hydrate (2/1/1), C53H50F2N6O10S2
  42. Crystal structure of 4-dimethylamino-pyridin-1-ium uracil-1-acetate, C13H16N4O4
  43. Crystal structure of dimethylammonium 5-fluorouracil-1-acetate, C8H12N3O4F
  44. Crystal structure of bis(N′-((5-(ethoxycarbonyl)-1H-pyrrol-2-yl)methylene)-N-ethylcarbamohydrazonothioato-κ2N,O)nickel(II), C22H30N8O4S2Ni
  45. Crystal structure of chlorido-(η5-pentamethylcyclopentadienyl)-((bis-pyrazol-1-yl)methane-κ2N,N′) rhodium(III) hexafluorophosphate. (C17H23ClN4RhF6P)
  46. The crystal structure of 5-(benzofuran-2-carbonyl)-N-cyclohexyl-5,6-dihydrophenanthridine-6-carboxamide, C29H26N2O3
  47. The crystal structure of 2-oxo-2H-chromen-4-yl acetate, C11H8O4
  48. The crystal structure of 2-nitroisophthalic acid, C8H5NO6
  49. Crystal structure of 3-fluoro-9-methoxy-4b,5,14,15-tetrahydro-6H-isoquinolino [2′,1′:1,6]pyrazino[2,3-b]quinoxaline, C19H17FN4O
  50. Crystal structure of (4-fluorobenzyl-κC)(bis(2-hydroxyethyl) carbamodithioato-κ2S,S′)(2,2′-imino-diethanolato-κ3N,O,O′)tin(IV), C16H25FN2O4S2Sn
  51. Crystal structure and anti-inflammatory activity of (3E,5E)-1-((4-bromophenyl)sulfonyl)-3-(pyridin-4-ylmethylene)-5-(2-(trifluoromethyl)benzylidene)piperidin-4-one, C25H18BrF3N2O3S
  52. Crystal structure and anti-inflammatory activity of (3E,5E)-1-((4-chlorophenyl)sulfonyl)-3-(pyridin-4-ylmethylene)-5-(2-(trifluoromethyl)benzylidene)piperidin-4-one, C25H18ClF3N2O3S
  53. The crystal structure of 3-((1R,2S)-1-methylpyrrolidin-1-ium-2-yl)pyridin-1-ium tetrachloridomanganate(II), C10H16Cl4MnN2
  54. The crystal structure of 3-carboxy-5-methylpyridin-1-ium-2-carboxylate, C8H7NO4
  55. Crystal structure of bis(3-methoxy-N-(1-(pyridin-2-yl)ethylidene)benzohydrazonato κ3O,N,N′)zinc(II), C30H28N6O4Zn
  56. Crystal structure of dichlorido-(4,4′-dichloro-2,2′-bipyridine-κ2N,N′)platinum(II) — acetone (1/1), C13H12Cl4N2PtO
  57. Crystal structure of diethyl 6,12-bis(4-fluorophenyl)-2,10-dimethoxy-3,9-diphenyl-3,9-diazatetracyclo[6.4.0.02,7.04,11]dodecane-1,5-dicarboxylate, C42H42F2N2O6
  58. Synthesis and crystal structure of (1E,3E)-2-hydroxy-5-methylisophthalaldehyde O,O-di(2-((((E)-(2-hydroxynaphthalen-1-yl)methylene)amino)oxy)ethyl) dioxime, C35H32N4O7
  59. The crystal structure of 2-phenyl-4,6-bis(prop-2-yn-1-yloxy)-1,3,5-triazine, C15H11N3O2
  60. Crystal structure of 7-(2-{4-[(4-bromophenyl)methyl]piperazin-1-yl}ethoxy)-2H-chromen-2-one, C22H23BrN2O3
  61. Crystal structure of bis-[N-(3-ethyl-1-pyrazin-2-yl-ethylidene)-3-bromo-benzoic acid-hydrazonato-κ3O,N,N′)]-cadmium(II), C30H28N8O2Br2Cd
  62. Crystal structure of 6-(4-fluorophenyl)-4-methoxy-2H-pyran-2-one, C12H9FO3
  63. Crystal structure of 3-methyl-3-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dien-1-yl)butanoic acid, C14H18O4
  64. The crystal structure of 3-bromo-6-methoxy-2-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine, C13H19BBrNO3
  65. The crystal structure of 6-methyl-3,20-dioxo-19-norpregna-4,6-dien-17-yl acetate–2,4-dihydroxybenzoic acid (1/1), C30H36O8
  66. The crystal structure of (5-chloro-2-hydroxy-N-(4-methoxy-2-oxidobenzylidene)benzohydrazonato-κ3N,O,O′)-(pyridine-κ1N)copper(II), C20H16ClCuN3O4
  67. Crystal structure of (E)-2-cyano-N′-(1-(3-ethylpyrazin-2-yl)ethylidene)acetohydrazide, C11H3N5O
  68. Crystal structure of (2,7-dihexyl-9,9-dimethyl-9H-xanthene-4,5-diyl)bis(diphenylphosphane), C51H56OP2
  69. Crystal structure of 5-((bis(pyridin-2-ylmethyl)amino)methyl)quinolin-8-ol, C22H20N4O
  70. Crystal structure of 3-(2-(5-(4-fluorophenyl)-3-(4-methylphenyl)-4,5-dihydro-1H-pyrazol-1-yl)thiazol-4-yl)-2H-chromen-2-one, C28H20FN3O2S
  71. The crystal structure of [(tetra-μ2-2,6-difluorobenzoato-κ2O:O′)-bis-(2,6-difluorobenzoato-κ2O:O′)-bis-(1,10-phenanthroline-κ2N:N′)]dierbium(III) C66H34N4O12F12Er2
  72. Crystal structure of bis(3-chloro-N-(1-(pyrazin-2-yl)ethylidene)benzohydrazonato-k3N,N′,O)nickel(II), C26H20N8O2Cl2Ni
  73. Crystal structure of (E)-3-(3-(5-methyl-1-phenyl-1H-1,2,3-triazol-4-yl)-1-phenyl-1H-pyrazol-4-yl)-1-phenylprop-2-en-1-one, C27H21N5O
  74. Crystal structure of (E)-N′-((4-aminophenyl)sulfonyl)-N,N-dimethylformimidamide, C9H13N3O2S
  75. Crystal structure of η6-p-cymene-iodido-(N-isopropyl-1-(pyridin-2-yl)methanimine-κ2N,N′)ruthenium(II) hexafluorophosphate(V), C19H26IN2F6Ru
  76. Crystal structure of 6-iodo-3-phenyl-2-propylquinazolin-4(3H)-one, C17H15IN2O
  77. Low temperature redetermination of the crystal structure of catena-poly[[tri-4-fluorobenzyltin(IV)]μ2-pyridine-4-carboxylato-κ2N:O], {C27H22F3NO2Sn}n
  78. Crystal structure of bis(2-propyl-1H-benzo[d]imidazol-3-ium) tetrachloridozincate(II), C10H13Cl4N2Zn
  79. The crystal structure of (Z)-3-hydrazono-5-nitroindolin-2-one – dimethyl sulfoxide (1/1), C8H6N4O3
  80. Crystal structure of bis-[N-(1-pyrazin-2-yl-ethylidene)-cyanoacetic acid-hydrazonato-κ3O,N,N′)]-zinc(II), C18H16N10O2Zn
  81. Crystal structure and photochromism of 1-(2,5-dimethyl-3-thienyl)-2-[2-methyl-5-(benzaldoxime)-3-thienyl] perfluorocyclopentene, C23H17F6NOS2
Heruntergeladen am 14.10.2025 von https://www.degruyterbrill.com/document/doi/10.1515/ncrs-2019-0756/html
Button zum nach oben scrollen